重庆大学附属人民医院（重庆市人民医院、重庆市医学科学院）副院长，研究员，博士生导师
邮箱：huhuaidong@sina.com
学习经历
2003.09-2006.07，重庆医科大学，内科学专业，博士；
1997.09-2000.07，重庆医科大学，内科学专业，硕士;
1989.09-1992.07，山东临沂医学专科学校，临床医学专业，专科;
工作经历
2021.10-至今，重庆市人民医院副院长、研究员
2017.12-2021.10，重庆医科大学附属第二医院院办公室主任
2015.05-2017.12重庆医科大学附属第二医院院办公室副主任（主持工作，其间，2016.12转聘为副研究员，2017.12聘为研究员）
2013.11-2014.04香港大学医学院访问学者
2007.06-2015.05重庆医科大学附属第二医院，科研处副处长（主持工作，其间，2007.10聘为副主任医师）；
2009.04-2009.08美国杰弗逊大学附属医院急救部，进修学习
2004.01-2007.06重庆医科大学附属第二医院科研处，科技科科长（主持科研处工作）；
2000.09-2004.01重庆医科大学附属第二医院科技科，副科长(主持科技科工作，2000.10聘为讲师)
2000.07-2000.09重庆医科大学附属第二医院科技科，科员
1992.08-1997.08山东省临沭县官庄乡卫生院内科工作（其间，1994.04加入中国共产党，1995.03聘为医师）
学术任职
中国营养保健食品协会体重管理专业委员会第一届副主任委员（2023.5-）
中国医药教育协会营养医学专业委员会第一届委员会常务委员（2018.4-2023.4）
中国营养学会骨营养与健康分会第一届委员会常务委员（2018.12-2022.12）
中国营养学会临床营养分会第七届委员会委员（2018.10-2022.10）
中国医疗保健国际交流促进会营养与代谢管理专业委员会常务委员(2015.1-2023.12)
吴阶平医学基金会营养学部肥胖管理专业委员会第一届常务委员（2017.09-2020.9）
重庆市医师协会营养医师分会第一届委员会副会长( 2016.12-2022.12)
中国抗衰老促进会女性健康专业委员会常务委员（2016.2-2020.2）
中国老年医学学会营养与食品安全分会常务委员(2015.11-2023.12)
中国老年医学学会内分泌代谢分会第一届委员会委员(2015.10-2018.10)
研究方向
1.老年肌少症综合干预临床应用示范研究
在国家重点研发计划课题（No：2020YFC2005605） 资助下，研究团队建立了覆盖中国东南西北4个汉族地区与4个民族地区(含高寒和高海拔地区)，实现肌少症全域全适龄的示范应用。通过开发推广肌少症干预方案，推动老年医学领域发展本项目开发并验证肌少症干预临床辅助决策智能系统，向社区及医院推广，探索创新干预措施，寻找肌少症治疗新方法。形成老年医学领域和数字化产业合作通过建立科学的老年肌少症多维管理体系，智能决策系统和平台，指导临床医生和养老从业人员正确管理衰弱，减少用药以及医疗费用开支，降低肌少症所致失能比例，节约失能照护费用，有助于实现健康中国战略。
2.人体新型生物标志物的临床研究
随着同位素标记相对和绝对定量等新兴蛋白质技术的发展，人体生物标志物的研究也得到极大发展，它们对于疾病的诊断和预后的价值也成为近年来的研究热点。利用蛋白质组学技术和分子生物学技术先后开展了肝癌新型标志物的研究、脓毒症诊断新型分子标志物的研究。结果证明，基于iTRAQ的蛋白质组学分析的分子相互作用蛋白网络有助于发现肝癌、脓毒血症等疾病早期诊断分子标志物，已发表相关SCI收录论著4篇。该研究已申请发明专利1项。
成果：（1.文章2.著作3.项目4.获奖）
（一）文章：（共发表SCI论文73篇，第一/通讯（含共同）27篇,*通讯作者）
2022年
1.He J, Zheng Z, Liu T, Ao Y, Yang Y,Hu H*. Salivary orosomucoid 1 as a biomarker of hepatitis B associated hepatocellular carcinoma. Sci Rep. 2022 Sep 12;12(1):15347. doi: 10.1038/s41598-022-18894-2. PMID: 36096917; PMCID: PMC9467997.
2.Fu L, Zhang W, Ao Y, Zheng Z,Hu H*. Efficacy of aerobic and resistance exercises in improving visceral adipose in patients with non-alcoholic fatty liver: a meta-analysis of randomized controlled trials. Z Gastroenterol. 2022 Nov;60(11):1644-1658. doi: 10.1055/a-1742-4257. Epub 2022 May 30. PMID: 35636454; PMCID: PMC9661875.
2021年
3.Tang Y, Ling N, Li S, Huang J, Zhang W, Zhang A, Ren H, Yang Y,Hu H, Wang X. A panel of urine-derived biomarkers to identify sepsis and distinguish it from systemic inflammatory response syndrome. Sci Rep. 2021 Oct 21;11(1):20794. doi: 10.1038/s41598-021-99595-0. PMID: 34675320; PMCID: PMC8531286.
2020年
4.Zhang W, Tang Y, Huang J,Hu H*.Efficacy of ursodeoxycholic acid in nonalcoholic fatty liver disease: An updated meta-analysis of randomized controlled trials. Asia Pac J Clin Nutr. 2020;29(4):696-705. doi: 10.6133/apjcn.202012_29(4).0004. PMID: 33377363.
5.Huang J, Tang Y, Zou X, Lu Y, She S, Zhang W, Ren H, Yang Y,Hu H*. Identification of the fatty acid synthase interaction network via iTRAQ-based proteomics indicates the potential molecular mechanisms of liver cancer metastasis. Cancer Cell Int. 2020 Jul 21;20:332. doi: 10.1186/s12935-020-01409-2. PMID: 32699531; PMCID: PMC7372886.
6.Zhang W, Huang J, Tang Y, Yang Y,Hu H*. Inhibition of fatty acid synthase (FASN) affects the proliferation and apoptosis of HepG2 hepatoma carcinoma cells via the β-catenin/C-myc signaling pathway. Ann Hepatol. 2020 Jul-Aug;19(4):411-416. doi: 10.1016/j.aohep.2020.03.005. Epub 2020 Mar 31. PMID: 32536483.
7.Zhang W, Tang Y, Huang J, Yang Y, Yang Q,Hu H*.Efficacy of inulin supplementation in improving insulin control, HbA1c and HOMA-IR in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. J Clin Biochem Nutr. 2020 May;66(3):176-183. doi: 10.3164/jcbn.19-103. Epub 2020 Mar 6. PMID: 32523243; PMCID: PMC7263925.
2019年
8.Tang Y, Huang J, Zhang WY, Qin S, Yang YX, Ren H,Yang QB*, Hu H*.Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2019 Sep 25;12:1756284819878046. doi: 10.1177/1756284819878046. PMID: 31598135; PMCID: PMC6764034.
9.Huang J, Qin S, Huang L, Tang Y, Ren H,Hu H*. Efficacy and safety of Rhizoma curcumea longae with respect to improving the glucose metabolism of patients at risk for cardiovascular disease: a meta-analysis of randomised controlled trials. J Hum Nutr Diet. 2019 Oct;32(5):591-606.
10.Shu F, Zou X, Tuo H, She S, Huang J, Ren H, Hu H, Peng S, Wang J, Yang Y. Stathmin gene silencing suppresses proliferation, migration and invasion of gastric cancer cells via AKT/sCLU and STAT3 signaling. Int J Oncol. 2019 Mar;54(3):1086-1098. doi: 10.3892/ijo.2019.4674. Epub 2019 Jan 3. PMID: 30628664.
2018年
11.Qin S, Huang L, Gong J, Shen S, Huang J, Tang Y, Ren H,Hu H*.Meta-analysis of randomized controlled trials of 4 weeks or longer suggest that curcumin may afford some protection against oxidative stress. Nutr Res. 2018 Dec;60:1-12. doi: 10.1016/j.nutres.2018.08.003. Epub 2018 Sep 4. PMID: 30527253.
2017年
12.Qin S, Huang L, Gong J, Shen S, Huang J, Ren H,Hu H*. Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials. Nutr J. 2017 Oct 11;16(1):68. doi: 10.1186/s12937-017-0293-y. PMID: 29020971; PMCID: PMC5637251.
13.Tuo H, Shu F, She S, Yang M, Zou XQ, Huang J, Hu HD, Hu P, Ren H, Peng SF, Yang YX. Sorcin induces gastric cancer cell migration and invasion contributing to STAT3 activation. Oncotarget. 2017 Oct 31;8(61):104258-104271. doi: 10.18632/oncotarget.22208. PMID: 29262638; PMCID: PMC5732804.
14.Yang M, Wang C, Li S, Xv X, She S, Ran X, Li S, Hu H, Hu P, Zhang D, Zheng Y, Yang Y, Ren H. Annexin A2 promotes liver fibrosis by mediating von Willebrand factor secretion. Dig Liver Dis. 2017 Jul;49(7):780-788. doi: 10.1016/j.dld.2017.02.013. Epub 2017 Feb 27. PMID: 28377286.
15.Shen S, Gong J, Yang Y, Qin S, Huang L, She S, Yang M, Ren H,Hu H*.Molecular mechanism of C-reaction protein in promoting migration and invasion of hepatocellular carcinoma cells in vitro. Int J Oncol. 2017 Apr;50(4):1289-1298. doi: 10.3892/ijo.2017.3911. Epub 2017 Mar 13. PMID: 28350119.
16.Gong J, Shen S, Yang Y, Qin S, Huang L, Zhang H, Chen L, Chen Y, Li S, She S, Yang M, Ren H,Hu H*.Inhibition of FASN suppresses migration, invasion and growth in hepatoma carcinoma cells by deregulating the HIF-1α/IGFBP1 pathway. Int J Oncol. 2017 Mar;50(3):883-892. doi: 10.3892/ijo.2017.3867. Epub 2017 Feb 2. PMID: 28197637.
17.Li S, Yang Y, Ding X, Yang M, She S, Peng H, Xu X, Ran X, Li S, Hu P, Hu H, Zhang D, Ren H. LHBs can elevate the expression of MDR1 through HIF-1α in patients with CHB infection: a comparative proteomic study. Oncotarget. 2017 Jan 17;8(3):4549-4562. doi: 10.18632/oncotarget.13941. PMID: 27999186; PMCID: PMC5354853.
18.Shen SS, Gong JJ, Wang XW, Chen L, Qin S, Huang LF, Chen YQ, Ren H, Yang QB,Hu HD*.Promotional effect of nonalcoholic fatty liver disease on Gallstone disease: A systematic review and meta-analysis.Turk J Gastroenterol. 2017 Jan;28(1):31-39. 0.869
2016年
19.Lei Y, Hu T, Song X, Nie H, Chen M, Chen W, Zhou Z, Zhang D, Hu H, Hu P, Ren H. Production of Autoantibodies in Chronic Hepatitis B Virus Infection Is Associated with the Augmented Function of Blood CXCR5+CD4+ T Cells. PLoS One. 2016 Sep 9;11(9):e0162241. doi: 10.1371/journal.pone.0162241. PMID: 27612199; PMCID: PMC5017876.
20.Zhang QF, Shao JY, Yin WW, Xia Y, Chen L, Wang X, Hu HD, Hu P, Ren H, Zhang DZ. Altered Immune Profiles of Natural Killer Cells in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. PLoS One. 2016 Aug 11;11(8):e0160171. doi: 10.1371/journal.pone.0160171. PMID: 27513564; PMCID: PMC4981347.
21.Shao JY, Yin WW, Zhang QF, Liu Q, Peng ML, Hu HD, Hu P, Ren H, Zhang DZ.Siglec-7 defines a highly functional natural killer cell subset and inhibits cell-mediated activities. Scand J Immunol. 2016 Sep;84(3):182-90.
22.Song XF, Hu TT, Lei Y, Li H, Zhang L, Zhang M, Liu B, Chen M, Hu HD, Ren H, Hu P. Activation of intrahepatic CD4+CXCR5+ T and CD19+ B cells is associated with viral clearance in a mouse model of acute hepatitis B virus infection. Oncotarget. 2016 Aug 9;7(32):50952-50962. doi: 10.18632/oncotarget.10688. PMID: 27447555; PMCID: PMC5239450.
23.Liu F, Wang XW, Chen L, Hu P, Ren H,Hu HD*.Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance. Aliment Pharmacol Ther. 2016 Jun;43(12):1253-61.
24.Yin W, Tong S, Zhang Q, Shao J, Liu Q, Peng H, Hu H, Peng M, Hu P, Ren H, Tian Z, Zhang D. Functional dichotomy of Vδ2 γδ T cells in chronic hepatitis C virus infections: role in cytotoxicity but not for IFN-γ production. Sci Rep. 2016 May 19;6:26296. doi: 10.1038/srep26296. PMID: 27192960; PMCID: PMC4872040.
25.Chen L, Wang X, Zhang Q, Gong J, Shen S, Yin W,Hu H*.Efficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-Analysis. Gastroenterol Res Pract. 2016;2016:7214020. doi: 10.1155/2016/7214020. Epub 2016 Jan 11. PMID: 26880896; PMCID: PMC4737451.
2015年
26.Liu F, Wang X, Wu G, Chen L, Hu P, Ren H,Hu H*.Coffee Consumption Decreases Risks for Hepatic Fibrosis and Cirrhosis: A Meta-Analysis. PLoS One. 2015 Nov 10;10(11):e0142457. doi: 10.1371/journal.pone.0142457. PMID: 26556483; PMCID: PMC4640566.
27.Liu F, Zou F, Wang X, Hu H, Hu P, Ren H. A model with combined viral and metabolic factors effectively predicts HBeAg status under long term entecavir therapy: a prospective cohort study. Virol J. 2015 Nov 2;12:179. doi: 10.1186/s12985-015-0409-y. PMID: 26527281; PMCID: PMC4630878.
28.Li H, Zhang HM, Chen LF, Chen YQ, Chen L, Ren H,Hu HD*.Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2015 Feb;39(1):80-92
29.Chen Y, Wu G, Zhang H, Xu H, Li H, Chen L, Yang Y, Hu P, Zhang D, Ren H,Hu H*. Interferon Treatment of Hepatitis C Reinfection after Liver Transplantation: A Meta-Analysis. Gastroenterol Res Pract. 2015;2015:206302. doi: 10.1155/2015/206302. Epub 2015 Jun 16. PMID: 26167174; PMCID: PMC4488578.
30.Ran X, Xu X, Yang Y, She S, Yang M, Li S, Peng H, Ding X, Hu H, Hu P, Zhang D, Ren H, Wu L, Zeng W. A quantitative proteomics study on olfactomedin 4 in the development of gastric cancer. Int J Oncol. 2015 Nov;47(5):1932-44. doi: 10.3892/ijo.2015.3168. Epub 2015 Sep 16. PMID: 26398045.
31.Peng H, Wei F, Liu JY, Hu HD, Ren H, Hu P. Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis. Hepatol Int. 2015 Oct;9(4):543-57. doi: 10.1007/s12072-015-9644-y. Epub 2015 Jul 11. PMID: 26162453.
32.Chen L, Chen Y, Wang X, Li H, Zhang H, Gong J, Shen S, Yin W,Hu H*.Efficacy and safety of oral branched-chain amino acid supplementation in patients undergoing interventions for hepatocellular carcinoma: a meta-analysis. Nutr J. 2015 Jul 9;14:67. doi: 10.1186/s12937-015-0056-6. PMID: 26155840; PMCID: PMC4496824.
33.Xiang Y, Liu Y, Yang Y, Hu H, Hu P, Ren H, Zhang D. A secretomic study on human hepatocellular carcinoma multiple drug-resistant cell lines. Oncol Rep. 2015 Sep;34(3):1249-60. doi: 10.3892/or.2015.4106. Epub 2015 Jul 3. PMID: 26151126.
34.She S, Xiang Y, Yang M, Ding X, Liu X, Ma L, Liu Q, Liu B, Lu Z, Li S, Liu Y, Ran X, Xu X, Hu H, Hu P, Zhang D, Ren H, Yang Y. C-reactive protein is a biomarker of AFP-negative HBV-related hepatocellular carcinoma. Int J Oncol. 2015 Aug;47(2):543-54. doi: 10.3892/ijo.2015.3042. Epub 2015 Jun 10. PMID: 26058824.
35.Chen M, Hu P, Ling N, Peng H, Lei Y, Hu H, Zhang D, Ren H. Enhanced functions of peripheral γδ T cells in chronic hepatitis B infection during interferon α treatment in vivo and in vitro. PLoS One. 2015 Mar 16;10(3):e0120086. doi: 10.1371/journal.pone.0120086. PMID: 25774808; PMCID: PMC4361562.
36.Liu JY, Sheng YJ, Ding XC, Tang H, Tong SW, Zhang DZ, Zhou Z, Hu P, Liao Y, Ren H,Hu HD*.The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: a meta-analysis. J Formos Med Assoc. 2015 Feb;114(2):164-73. doi: 10.1016/j.jfma.2012.10.007. Epub 2012 Dec 20. PMID: 25678179.
2014年
37.Xiang Z, Liu Y, Zheng J, Liu M, Lv A, Gao Y, Hu H, Lam KT, Chan GC, Yang Y, Chen H, Tsao GS, Bonneville M, Lau YL, Tu W. Targeted activation of human Vγ9Vδ2-T cells controls epstein-barr virus-induced B cell lymphoproliferative disease. Cancer Cell. 2014 Oct 13;26(4):565-76. doi: 10.1016/j.ccr.2014.07.026. Epub 2014 Sep 11. PMID: 25220446.
38.Guo L, Wang X, Ren L, Zeng M, Wang S, Weng Y, Tang Z, Wang X, Tang Y, Hu H, Li M, Zhang C, Liu C. HBx affects CUL4-DDB1 function in both positive and negative manners. Biochem Biophys Res Commun. 2014 Aug 8;450(4):1492-7. doi: 10.1016/j.bbrc.2014.07.019. Epub 2014 Jul 11. PMID: 25019988.
39.Hu H, Ding X, Yang Y, Zhang H, Li H, Tong S, An X, Zhong Q, Liu X, Ma L, Liu Q, Liu B, Lu Z, Zhang D, Hu P, Ren H*. Changes in glucose-6-phosphate dehydrogenase expression results in altered behavior of HBV-associated liver cancer cells.Am J PhysiolGastrointest Liver Physiol. 2014 Sep 15;307(6):G611-22.
40.Wang X, Liu F, Wei F, Ren H,Hu H*.Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis. PLoS One. 2014 Jun 25;9(6):e100128. doi: 10.1371/journal.pone.0100128. PMID: 24963667; PMCID: PMC4070902.
41.Liu Y, Wang X, Li S, Hu H, Zhang D, Hu P, Yang Y, Ren H. The role of von Willebrand factor as a biomarker of tumor development in hepatitis B virus-associated human hepatocellular carcinoma: a quantitative proteomic based study. J Proteomics. 2014 Jun 25;106:99-112. doi: 10.1016/j.jprot.2014.04.021. Epub 2014 Apr 24. PMID: 24769235.
42.Wei F, Liu J, Liu F, Hu H, Ren H, Hu P. Interferon-based anti-viral therapy for hepatitis C virus infection after renal transplantation: an updated meta-analysis. PLoS One. 2014 Apr 3;9(4):e90611. doi: 10.1371/journal.pone.0090611. PMID: 24699257; PMCID: PMC3974660.
43.Liu F, Wang X, Wei F, Hu H, Zhang D, Hu P, Ren H. Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis. Virol J. 2014 Mar 28;11:59. doi: 10.1186/1743-422X-11-59. PMID: 24673792; PMCID: PMC3986697.
44.Hu TT, Song XF, Lei Y, Hu HD, Ren H, Hu P. Expansion of circulating TFH cells and their associated molecules: involvement in the immune landscape in patients with chronic HBV infection. Virol J. 2014 Mar 21;11:54. doi: 10.1186/1743-422X-11-54. PMID: 24655429; PMCID: PMC3994480.
45.Zhong Q, An X, Yang YX, Hu HD, Ren H, Hu P. Keratin 8 is involved in hepatitis B virus replication. J Med Virol. 2014 Apr;86(4):687-94. doi: 10.1002/jmv.23873. Epub 2013 Dec 30. PMID: 24375072.
46.Peng H, Liu J, Yang M, Tong S, Yin W, Tang H, Hu P,Hu H*, Ren H*.Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis. J Clin Pharmacol. 2014 Feb;54(2):189-200. doi: 10.1002/jcph.181. Epub 2013 Oct 4. PMID: 24105676.
47.Li H, Zhang HM, Chen LF, Chen YQ, Chen L, Ren H,Hu HD*.Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2015 Feb;39(1):80-92. doi: 10.1016/j.clinre.2014.07.010. Epub 2014 Sep 4. PMID: 25199680.
48.Hu H, Ding X, Yang Y, Zhang H, Li H, Tong S, An X, Zhong Q, Liu X, Ma L, Liu Q, Liu B, Lu Z, Zhang D, Hu P,Ren H*.Changes in glucose-6-phosphate dehydrogenase expression results in altered behavior of HBV-associated liver cancer cells. Am J Physiol Gastrointest Liver Physiol. 2014 Sep 15;307(6):G611-22. doi: 10.1152/ajpgi.00160.2014. Epub 2014 Jul 3. PMID: 24994855.
2013年
49.Zhang H, Li H, Yang Y, Li S, Ren H, Zhang D,Hu H*.Differential regulation of host genes including hepatic fatty acid synthase in HBV-transgenic mice. J Proteome Res. 2013 Jun 7;12(6):2967-79. doi: 10.1021/pr400247f. Epub 2013 May 23. PMID: 23675653.
50.Liu MH, Sheng YJ, Liu JY, Hu HD, Zhang QF, Ren H. Efficacy of telbivudine on interruption of hepatitis B virus vertical transmission: a meta-analysis. Ann Saudi Med. 2013 Mar-Apr;33(2):169-76. doi: 10.5144/0256-4947.2013.169. PMID: 23563007; PMCID: PMC6078630.
51.Zhang L, Yang M, Ren H, Hu H, Boden G, Li L, Yang G. GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK. Liver Int. 2013 May;33(5):794-804. doi: 10.1111/liv.12120. Epub 2013 Feb 24. PMID: 23432843.
52.Tong SW, Yang YX,Hu HD, An X, Ye F, Ren H, Li SL, Zhang DZ*. HSPB1 is an intracellular antiviral factor against hepatitis B virus. J Cell Biochem. 2013 Jan;114(1):162-73.
2012年
53.Liu JY, Sheng YJ, Hu HD, Zhong Q, Wang J, Tong SW, Zhou Z, Zhang DZ, Hu P, Ren H. The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis. Virol J. 2012 Sep 6;9:186. doi: 10.1186/1743-422X-9-186. PMID: 22950520; PMCID: PMC3511228.
54.Wang LN, Tong SW, Hu HD, Ye F, Li SL, Ren H, Zhang DZ, Xiang R, Yang YX. Quantitative proteome analysis of ovarian cancer tissues using a iTRAQ approach. J Cell Biochem. 2012 Dec;113(12):3762-72. doi: 10.1002/jcb.24250. PMID: 22807371.
55.Diang XC, Ma LN, Li YF, Liu XY, Zhang X, Liu JY, Sheng YJ, Zhang DZ, Hu HD, Ren H. Association between serum platelet-derived growth factor BB and degree of liver damage, fibrosis and hepatitis B e antigen (HBeAg) status in CHB patients. Hepatogastroenterology. 2012 Nov-Dec;59(120):2357-60. doi: 10.5754/hge12388. PMID: 22688015.
56.Chen M, Hu P, Peng H, Zeng W, Shi X, Lei Y, Hu H, Zhang D, Ren H. Enhanced peripheral γδT cells cytotoxicity potential in patients with HBV-associated acute-on-chronic liver failure might contribute to the disease progression. J Clin Immunol. 2012 Aug;32(4):877-85. doi: 10.1007/s10875-012-9678-z. Epub 2012 Mar 14. PMID: 22415432.
57.Tong SW, Yang YX, Hu HD, An X, Ye F, Hu P, Ren H, Li SL, Zhang DZ. Proteomic investigation of 5-fluorouracil resistance in a human hepatocellular carcinoma cell line. J Cell Biochem. 2012 May;113(5):1671-80. doi: 10.1002/jcb.24036. PMID: 22189913.
2011年
58.Li S, Hu P, Zhang QQ, Liu YH,Hu HD, Zhang DZ, Ren H. Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B. Hepat Mon. 2011 Mar;11(3):163-72. PMID: 22087138; PMCID: PMC3206691.
59.Ye F, Yang YX,Hu HD, Tong JB, Cai WJ, Zhang DZ, Hu P, Li SL, Ren H. Preparation of novel anti-ski monoclonal antibodies. Hybridoma (Larchmt). 2011 Aug;30(4):393-5. doi: 10.1089/hyb.2011.0034. PMID: 21851241.
60.Ye F, Yang YX, Hu HD, Tong JB, Cai WJ, Zhang DZ, Hu P, Li SL, Ren H*. Preparation of novel anti-ski monoclonal antibodies.Hybridoma (Larchmt). 2011 Aug;30(4):393-5.
61.Sheng YJ, Liu JY, Tong SW,Hu HD, Zhang DZ, Hu P, Ren H. Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Virol J. 2011 Aug 8;8:393. doi: 10.1186/1743-422X-8-393. PMID: 21824397; PMCID: PMC3173393.
62.Zhang QQ, An X, Liu YH, Li SY, Zhong Q, Wang J,Hu HD, Zhang DZ, Ren H, Hu P. Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol J. 2011 Feb 15;8:72. doi: 10.1186/1743-422X-8-72. PMID: 21324130; PMCID: PMC3046930.
2010年
63.Hu HD, Ye F, Zhang DZ, Hu P, Ren H, Li SL. iTRAQ quantitative analysis of multidrug resistance mechanisms in human gastric cancer cells. J Biomed Biotechnol. 2010;2010:571343. doi: 10.1155/2010/571343. Epub 2010 Jun 6. PMID: 20625496; PMCID: PMC2896698.
64.Qing Y, Chen M, Zhao J,Hu H, Xu H, Ling N, Peng M, Ren H. Construction of an HBV DNA vaccine by fusion of the GM-CSF gene to the HBV-S gene and examination of its immune effects in normal and HBV-transgenic mice. Vaccine. 2010 Jun 11;28(26):4301-7. doi: 10.1016/j.vaccine.2010.04.023. Epub 2010 Apr 27. PMID: 20430121.
65.Li SL, Ye F, Cai WJ,Hu HD, Hu P, Ren H, Zhu FF, Zhang DZ. Quantitative proteome analysis of multidrug resistance in human ovarian cancer cell line. J Cell Biochem. 2010 Mar 1;109(4):625-33. doi: 10.1002/jcb.22413. PMID: 20082317.
2009年
66.Hu P,Hu HD, Chen M, Peng ML, Tang L, Tang KF, Matsui M, Belladonna ML, Yoshimoto T, Zhang DZ, Xiang R, Ren H. Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Mol Immunol. 2009 May;46(8-9):1654-62. doi: 10.1016/j.molimm.2009.02.025. Epub 2009 Mar 18. PMID: 19299021.
67.Yang YX, Sun XF, Cheng AL, Zhang GY, Yi H, Sun Y,Hu HD, Hu P, Ye F, Chen ZC, Xiao ZQ*. Increased expression of HSP27 linked to vincristine resistance in human gastric cancer cell line. J Cancer Res Clin Oncol. 2009 Feb;135(2):181-9.
68.Hu P, Peng ML, Chen M,Hu HD, Tang L, Tang KF, Ren H. Molecular cloning, expression and characterization of an interleukin 27 p28 homolog in pig (Sus scrofa). Vet Immunol Immunopathol. 2009 Aug 15;130(3-4):262-7. doi: 10.1016/j.vetimm.2009.02.009. Epub 2009 Feb 14. PMID: 19269039.
2008年
69.Chen M, Zhang D, Zhen W, Shi Q, Liu Y, Ling N, Peng M, Tang K, Hu P,Hu H, Ren H. Characteristics of circulating T cell receptor gamma-delta T cells from individuals chronically infected with hepatitis B virus (HBV): an association between V(delta)2 subtype and chronic HBV infection. J Infect Dis. 2008 Dec 1;198(11):1643-50. doi: 10.1086/593065. PMID: 18954265.
2007年
70.Yang YX,Hu HD, Zhang DZ, Ren H. Identification of proteins responsible for the development of adriamycin resistance in human gastric cancer cells using comparative proteomics analysis. J Biochem Mol Biol. 2007 Nov 30;40(6):853-60. doi: 10.5483/bmbrep.2007.40.6.853. PMID: 18047778.
71.Tang L,Hu HD, Hu P, Lan YH, Peng ML, Chen M, Ren H*. Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma. Gene Ther. 2007 Aug;14(16):1226-34.
72.Tang KF, Wang Y, Wang P, Chen M, Chen Y,Hu HD, Hu P, Wang B, Yang W, Ren H. Upregulation of PHLDA2 in Dicer knockdown HEK293 cells. Biochim Biophys Acta. 2007 May;1770(5):820-5. doi: 10.1016/j.bbagen.2007.01.004. Epub 2007 Jan 17. PMID: 17303335.
73.Lan YH, Li YG, Liang ZW, Chen M, Peng ML, Tang L,Hu HD,Ren H. A DNA vaccine against chimeric AFP enhanced by HSP70 suppresses growth of hepatocellular carcinoma. Cancer Immunol Immunother. 2007 Jul;56(7):1009-16. doi: 10.1007/s00262-006-0254-3. Epub 2006 Dec 22. PMID: 17186291.
（三）著作
肥胖症治疗/朱翠凤，胡怀东，石汉平 主编 北京：人民卫生出版社，2023.2，ISBN 978-7-117-34053-3，中国版本图书馆CIP数据核字（2022）第219055号
（四）项目
1.国家重点研发计划（编号：2020YFC2005605），课题名称：老年肌少症综合干预应用示范研究，起止时间：7/01/2020-30/06/2023，课题负责人，经费：413万元。
2.国家自然科学基金(编号：81171560)，课题名称：G6PD及其相互作用蛋白在乙型肝炎病毒复制中的机制研究，起止时间：01/01/2012-31/12/2015，课题负责人 ，经费：58万元。
3.国家科技重大专项（编号：2008ZX10002-006），慢性乙型肝炎临床转归及相关影响因素的研究，起止时间：01/11/2008-30/04/2012，主研人员，排名第三，经费：3020万元。
4.国家科技重大专项（编号：2012ZX10002-007-001），课题名称：病毒性肝炎转归预警预测的研究，起止时间：01/05/2012-31/12/2015，主研人员，排名第三，经费：2047万元。
5.国家科技支撑计划子课题（编号：2012BAI35B03），课题名称：感染性疾病个体化营养治疗关键技术与评价研究，2012.07-31/12/2015，主研人员，排名第二，经费：45万元。
6.国家自然科学基金（编号：30930082），课题名称：乙型肝炎免疫应答的细胞及分子调控网络与通路研究，起止时间01/01/2010-31/12/2013，主研人员，排名第三，经费：180万元。
7.国家自然科学基金（编号：30771923），课题名称：应用高通量质谱蛋白质复合体分析方法鉴定与乙肝病毒X蛋白相互作用的蛋白质分子，起止时间：01/01/2008-31/12/2011，主研人员，排名第三，经费：24万元。
8.国家自然科学基金（编号：30671869），课题名称：NK-DC Cross-talk在乙型肝炎病毒感染慢性化过程中的作用，起止时间：01/01/2007-31/12/2010，主研人员，排名第三，经费35万元。
9.国家自然科学基金（编号：30672389），课题名称：TAMs新型特异分子标志物的分离鉴定及其靶向抗乳腺癌治疗的实验研究，起止时间：01/01/2007-31/12/2010，主研人员，排名第二，经费32万元。
10.国家自然科学基金（编号：30900507），课题名称：高通量质谱蛋白质复合体分析方法鉴定抵抗素作用受体，起止时间：01/01/2010-31/12/2012，主研人员，排名第二，经费20万元。
11.国家自然科学基金（编号：30801348），课题名称：Sorcin蛋白在胃癌耐药细胞中的相互作用网络研究，起止时间：01/01/2009-31/12/2011，主研人员，排名第三，经费20万元。
12.重庆市自然科学基金（编号：cstc2011jjA10025），课题名称：G6PD及其相互作用蛋白在乙型肝炎病毒复制中的机制研究，起止时间：01/01/2012-31/12/2014，课题负责人，经费：5万元。
13.重庆市自然科学基金(编号：CSTC2011BB5140)，HPX在脑出血后继发性脑损伤中的保护作用及其机制研究，起止时间：01/01/2012-31/12/2014，主研人员，排名第二，经费：5万元。
（四）获奖
1.完成人：任红，张大志，胡怀东，胡鹏，唐开福，陈敏，许红梅，彭明利，张定凤，李用国，唐俐。项目名称：慢性乙型肝炎发生、发展的免疫学机制及治疗新策略研究。获奖单位：重庆医科大学。获得2011年度重庆市科技进步奖一等奖（证书号：2011-J-1-08-D01）、2011年中华医学科技奖二等奖（证书号：201102134U0101）、2011年教育部科技进步奖二等奖（证书号：2011-274）。
2.完成人：王玉君，严钟德，刘东方，胡怀东。项目名称：糖尿病慢性并发症的临床研究。获奖单位：重庆医科大学。获得2002年度重庆市科技进步奖三等奖（证书号：023418）。
3.完成人：陈秋、徐勇、胡怀东、牟殷正、廖国伟。项目名称：糖尿病肾病发病机制与早期诊断研究。获奖单位：泸州医学院附属医院、重庆医科大学附二院。获得2005-2006年度泸州市科技进步奖一等奖（证书号：2005-2006 1-3-3）。
